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Objectives The goal of this study was to determine whether residual risk after high-dose statin therapy for primary prevention individu-
als with reduced levels of low-density lipoprotein cholesterol (LDL-C) is related to on-treatment apolipoprotein B, non–high-
density lipoprotein cholesterol (non–HDL-C), trigylcerides, or lipid ratios, and how they compare with on-treatment LDL-C.
Background Guidelines focus on LDL-C as the primary target of therapy, yet residual risk for cardiovascular disease (CVD)
among statin-treated individuals remains high and not fully explained.
Methods Participants in the randomized placebo-controlled JUPITER (Justification for the Use of Statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial were adults without diabetes or CVD, with baseline LDL-C levels
130 mg/dl, high-sensitivity C-reactive protein levels 2 mg/l, and triglyceride concentrations 500 mg/dl.
Individuals allocated to receive rosuvastatin 20 mg daily with baseline and on-treatment lipids and lipoproteins
were examined in relation to the primary endpoint of incident CVD (nonfatal myocardial infarction or stroke, hos-
pitalization for unstable angina, arterial revascularization, or cardiovascular death).
Results Using separate multivariate Cox models, statistically significant associations of a similar magnitude with residual risk
of CVD were found for on-treatment LDL-C, non–HDL-C, apolipoprotein B, total cholesterol/HDL-C, LDL-C/HDL-C, and
apolipoprotein B/A-I. The respective adjusted standardized hazard ratios (95% confidence intervals) for each of these
measures were 1.31 (1.09 to 1.56), 1.25 (1.04 to 1.50), 1.27 (1.06 to 1.53), 1.22 (1.03 to 1.44), 1.29 (1.09 to
1.52), and 1.27 (1.09 to 1.49). The overall residual risk and the risk associated with these measures decreased
among participants achieving on-treatment LDL-C 70 mg/dl, on-treatment non–HDL-C 100 mg/dl, or on-
treatment apolipoprotein B 80 mg/dl. In contrast, on-treatment triglycerides showed no association with CVD.
Conclusions In this primary prevention trial of nondiabetic individuals with low LDL-C and elevated high-sensitivity C-reactive pro-
tein, on-treatment LDL-C was as valuable as non–HDL-C, apolipoprotein B, or ratios in predicting residual risk. (JUPI-
TER—Crestor 20mg Versus Placebo in Prevention of Cardiovascular [CV] Events; NCT00239681) (J Am Coll Cardiol
2012;59:1521–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.035Statins are the most widely used lipid-lowering agents and the
standard of care for individuals with dyslipidemia or prior
cardiovascular disease (CVD) or who are at high-risk for CVD
(1,2). Current guidelines focus on reducing low-density lipo-
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tailoring the level of optimal LDL-C reduction to the indi-
vidual’s level of cardiovascular risk. Nonetheless, the risk
among statin-treated individuals remains high and has been
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incidence rate of a major CVD
event occurring among statin-
treated patients in randomized
clinical trials is 1 in 5 (22%) for
individuals with prior CVD and 1
in 10 (10%) for individuals with no
prior CVD (3,4).
Residual risk after statin treat-
ment may be related to the on-
treatment concentrations of lip-
ids, apolipoproteins, or other
biomarkers beyond LDL-C (5).
In a recent analysis from the JUPITER (Justification for the
Use of Statins in Prevention: An Intervention Trial Evalu-
ating Rosuvastatin) trial, on-treatment concentrations of
high-sensitivity C-reactive protein (hsCRP) were predictive
of residual risk among primary prevention individuals
treated with potent statin therapy (6), but on-treatment
high-density lipoprotein cholesterol (HDL-C) and apoli-
poprotein A-I were not (7). It is possible that other lipid or
apolipoprotein measures, such as the LDL-C/HDL-C ratio
or apolipoprotein B/A-I ratio, may provide better risk
information than HDL-C or apolipoprotein A-I alone (8).
Furthermore, apolipoprotein B has been proposed as a
therapeutic target for lipid lowering (9,10). Apolipoprotein
B reflects the number of potentially atherogenic lipoprotein
particles, because each very-low-density lipoprotein and
LDL particle carries on its surface one apolipoprotein B
molecule (11). On-treatment apolipoprotein B has been
compared with LDL-C in asymptomatic individuals for the
primary prevention of CVD among statin-treated individ-
uals with low HDL-C in the AFCAPS/TexCAPS (Air
Force/Texas Coronary Atherosclerosis Prevention Study)
trial (12) and among patients with diabetes in the CARDS
(Collaborative Atorvastatin Diabetes Study) trial (13). In
AFCAPS/TexCAPS, on-treatment apolipoprotein B was a
better predictor of events compared with LDL-C, but
comparison with non–HDL-C was not reported (9,12). In
contrast, among statin-treated patients in CARDS, none of
the on-treatment lipids or apolipoproteins were statistically
significantly associated with events (13).
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lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterold
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2011, accepted December 20, 2011.Among patients with stable coronary disease treated with
potent statin therapy, apolipoprotein B and non–HDL-C
were comparable as predictors of residual risk (14). But it is
uncertain if apolipoprotein B or non–HDL-C are better
targets of therapy compared with LDL-C for the primary
prevention of CVD among nondiabetic individuals with low
LDL-C treated with potent statin therapy.
This analysis of the JUPITER trial cohort addressed, in a
primary prevention setting of nondiabetic individuals with
baseline low LDL-C but elevated hsCRP, whether residual
risk after high-dose statin therapy was related to on-treatment
levels of apolipoprotein B, non–HDL-C, trigylcerides, or lipid
ratios, and how they compared with on-treatment LDL-C. A
secondary goal was to explore residual risk associations of these
measures among the subgroup of individuals who achieved
very low cholesterol targets while undergoing statin therapy.
Methods
Study population. The JUPITER design has been previ-
ously published (15–17). Asymptomatic individuals (women
age 60 years, men age 50 years) with no history of
oronary disease, stroke, or diabetes and who had LDL-C
evels 130 mg/dl, hsCRP levels 2.0 mg/l, and triglycer-
de concentrations 500 mg/dl were randomized. Those
atients currently using hormone therapy or with previous
r current use of lipid-lowering therapy or immunosuppres-
ant agents were excluded. Family history of premature
therosclerosis was defined as coronary disease in a first-
egree relative (men age 55 years or women age 65
ears). Of the 8,901 individuals randomized to receive
osuvastatin therapy, individuals were included who had
oth baseline and on-treatment 1-year measures for all the
ipid and lipoprotein variables examined, resulting in a
ample size of 7,832.
aboratory measurements. Measurements were per-
ormed in a central laboratory on blood samples collected
fter patient fasting of at least 8 h (18). Concentrations of
polipoproteins B and A-I were measured via immunon-
phelometry by using a Behring nephelometric assay (Mar-
urg, Germany). An enzymatic procedure (cholesterol es-
erase) with a colorimetric endpoint was used to assess total
holesterol. Triglycerides were measured with an enzymatic
ydrolysis procedure to obtain a colorimetric endpoint
riglyceride value. HDL-C was measured in the resulting
upernatant after heparin–manganese precipitation of apo-
ipoprotein B–containing proteins. LDL-C concentrations
ere calculated by using the Friedewald equation when
riglycerides were 400 mg/dl (19) and measured by ultra-
entrifugation when triglycerides were 400 mg/dl. A
igh-sensitivity assay (Behring) nephelometer was used for
easurement of hsCRP.
utcomes. The trial was expected to last approximately 5
ears, but on March 30, 2008, the Independent Data and
afety Monitoring Board terminated the trial early upon
etermination that the accumulated evidence from the trial
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doubt that rosuvastatin was indicated for a specified group
of participants (after 1.9 years of median follow-up; maxi-
mal follow-up of 5.0 years). Follow-up included structured
interviews assessing outcomes. The primary endpoint of the
JUPITER trial was a composite endpoint (CVD), defined
as the combined endpoint of myocardial infarction, stroke,
hospitalization for unstable angina, arterial revasculariza-
tion, or cardiovascular death. For this analysis, we also
examined the expanded secondary endpoint of CVD or
death. Myocardial infarction, stroke, and CVD death were
confirmed according to standard criteria. Unstable angina
was ischemic chest pain at rest or with minimal exertion
occurring within the preceding 48 hours requiring hospital-
ization and the presence of objective evidence of ischemia.
Arterial revascularization was coronary artery bypass graft
surgery, bypass grafting of any peripheral artery or carotid
artery, or the performance of at least one percutaneous
transluminal intervention. All reported primary endpoints
that occurred through March 30, 2008, were adjudicated by
an independent endpoint committee blinded to randomized
treatment assignment.
Statistical analyses. Statistical analyses were performed
with SAS version 9.1 (SAS Institute, Inc., Cary, North
Carolina). Medians, 25th, and 75th percentiles were calcu-
lated for continuous variables. Statistical comparisons were
made with the sign tests for comparing the change from
baseline with on-treatment values.
Statistical tests for outcomes were performed according to
intention-to-treat analyses. The exposure time was calcu-
lated as the time from randomization to occurrence of the
primary endpoint or the date of death, last study visit,
withdrawal, loss to follow-up, or March 30, 2008, which-
ever came first. Absolute event rates were calculated per 100
person-years. Cox proportional hazards models were used to
calculate the hazard ratios and 95% confidence intervals
(CIs). All regression analyses were adjusted for age, sex,
Lipids, Apolipoproteins, and Ratios Among 7,83Ind viduals With Baseline and 1-Year MeasuresTable 1 Lipids, Apolipoprotein , and RatioIndividuals With Baseline and 1-Yea
Variables Baseline
Lipids (mg/dl)
TC 186 (169, 200) 1
LDL-C 108 (94, 119)
Non–HDL-C 134 (118, 147)
Triglycerides 118 (85, 169)
HDL-C 49 (40, 60)
Apolipoproteins (mg/dl)
Apolipoprotein A-I 163 (144, 185) 1
Apolipoprotein B 109 (95, 122)
Ratios
TC/HDL-C 3.67 (3.06, 4.41) 2
LDL-C/HDL-C 2.14 (1.69, 2.64) 1
Apolipoprotein B/A-I 0.66 (0.55, 0.80) 0Values are median (25th, 75th percentile).
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotesmoking status, family history of premature atherosclerosis,
body mass index, systolic blood pressure, and fasting glu-
cose. Each lipid measure was examined in tertiles and as
continuous variables (per 1 SD). P values for linear trends
were obtained using the median value for each tertile. All p
values were 2-tailed. The likelihood ratio chi-square statistic
was also used to evaluate the significance of individual lipid
measures.
We conducted 2 additional exploratory analyses to eval-
uate the following: 1) whether any measure of on-treatment
lipids was significantly related to residual risk after control-
ling for on-treatment LDL-C; and 2) whether on-
treatment lipid measures remained associated with risk
among individuals who achieved clinically accepted
guideline-recommended cutoff points for LDL-C (100 or
70 mg/dl ), non–HDL-C (130 or 100 mg/dl), or
polipoprotein B (90 or 80 mg/dl).
esults
he baseline characteristics for individuals randomly allo-
ated to receive rosuvastatin and who had on-treatment
ipid and lipoprotein measurements available for analysis at
aseline and 1 year were similar to the overall JUPITER
tudy population (17,20). The JUPITER patients were
elected to have an LDL-C 130 mg/dl and triglycerides
500 mg/dl, and hence the total cholesterol, LDL-C, and
on–HDL-C were all low (respective median baseline
oncentrations of 186, 108, and 134 mg/dl, respectively).
he apolipoprotein B levels were not low (median baseline
oncentration 109 mg/dl). Random allocation to the rosu-
astatin group in the JUPITER trial decreased median
n-treatment concentrations of total cholesterol, LDL-C,
nd non–HDL-C to a similar extent on a mass concentra-
ion scale (–50 mg/dl, –50 mg/dl, and –54 mg/dl, respec-
ively) and reduced apolipoprotein B by 41 mg/dl (Table 1).
here was greater proportional LDL-C lowering (46.2%)
suvastatin-TreatedLipid Variables Examinedg 7,832 Rosuvast tin-Treated
asures of All Lipid Variables Examined
ar 1 Change p Value
16, 155) –50 (–67, –27) 0.0001
4, 71) –50 (–63, –29) 0.0001
4, 96) –54 (–70, –31) 0.0001
4, 137) –17 (–48, 5) 0.0001
3, 64) 3 (–2, 8) 0.0001
45, 188) 2 (–12, 16) 0.0001
6, 81) –41 (–54, –24) 0.0001
.10, 3.05) –1.11 (–1.65, –0.61) 0.0001
.78,1.46) –1.02 (–1.44, –0.57) 0.0001
.32,0.52) –0.25 (–0.35, –0.14) 0.00012 Roof AllAm n
r Me
Ye
33 (1
55 (4
76 (6
99 (7
52 (4
65 (1
66 (5
.50 (2
.05 (0
.40 (0in cholesterol; TC  total cholesterol.
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Lipids, Apolipoproteins, and Residual Risk April 24, 2012:1521–8compared with non–HDL-C (40.3%) or apolipoprotein B
(37.6%) with rosuvastatin therapy. Triglycerides were also
reduced but to a lesser extent.
The primary endpoint was reduced with rosuvastatin by
44% (p 0.001) (17). Table 2 displays CVD incidence rates
nd associations for each of the on-treatment lipids, apoli-
oproteins, and ratios (examined in tertiles) with incident
vents obtained from separate Cox regression models that
djusted for nonlipid risk factors. Generally similar and
ignificant associations were obtained for on-treatment
oncentrations of LDL-C, non–HDL-C, and apolipopro-
ein B with CVD. By contrast, on-treatment triglycerides,
DL-C, and apolipoprotein A-I showed no associations
ith CVD risk. Similar results were noted for the expanded
econdary endpoint of CVD or death, except that apolipo-
rotein A-I now became statistically significant and the
polipoprotein B/A-I ratio now had a greater magnitude of
ssociation (2.12 [95% CI: 1.44 to 3.12]).
When lipids, apolipoproteins, and ratios were examined
s standardized continuous variables, results were generally
imilar for LDL-C, non–HDL-C, apolipoprotein B, and
he ratios (Table 3), as were the goodness-of-fit likelihood
atio chi-square statistics that added each of these variables
o a model with only nonlipid risk factors. Specifically, for
n-treatment LDL-C, non–HDL-C, apolipoprotein B,
nd the ratios (total cholesterol/HDL-C, LDL-C/HDL-C,
nd apolipoprotein B/A-I), the respective adjusted stan-
ardized hazard ratios (95% CIs) were 1.31 (1.09 to 1.56),
.25 (1.04 to 1.50), 1.27 (1.06 to 1.53), 1.22 (1.03 to 1.44),
.29 (1.09 to 1.52), and 1.27 (1.09 to 1.49).
Two exploratory analyses were also conducted. First, we
ssessed whether any of the measures (non–HDL-C, apo-
ipoprotein B, total cholesterol/HDL-C, LDL-C/HDL-C,
r apolipoprotein B/A-I) was significantly related to resid-
al risk after controlling for on-treatment LDL-C. In
odels that included on-treatment LDL-C, none of the
ther lipid measures remained statistically significant.
Subsequently, we compared associations with residual
isk among the subgroups of individuals who achieved the
linical recommendations for LDL-C targets or the alter-
ative recommended targets for non–HDL-C or apolipo-
rotein B. As shown in Table 4, among the subgroups of
individuals achieving the lower clinical targets (LDL-C
70 mg/dl, non–HDL-C100 mg/dl, or apolipoprotein B
80 mg/dl), the magnitude of residual risk was small, and
he residual risk associated with these measures became
ttenuated and mostly no longer statistically significant.
polipoprotein B/A-I retained its association with the
xpanded secondary endpoint of CVD or death, but this
nding was also attenuated in the subgroup of individuals
ho achieved apolipoprotein B 80 mg/dl on therapy.
iscussion
n the JUPITER trial of primary prevention nondiabetic
ndividuals with low LDL-C and high hsCRP, measur- Ting on-treatment LDL-C was as valuable as measuring
non–HDL-C or apolipoprotein B, or the ratios (total
cholesterol/HDL-C, LDL-C/HDL-C, and apolipoprotein
B/A-I) in relation to residual risk of CVD. The magnitude
of the overall residual risk and the risk associated with these
measures decreased after achieving on-treatment concentra-
tions of LDL-C 70 mg/dl, non–HDL-C 100 mg/dl, or
apolipoprotein B 80 mg/dl. Furthermore, the current
findings do not support the hypothesis that on-treatment
triglycerides are related to residual risk among nondiabetic
primary prevention individuals with baseline triglyceride
levels 500 mg/dl and elevated hsCRP who are treated
with potent statin therapy; however, median on-treatment
triglycerides was low (118 mg/dl).
Optimal targets of statin therapy. It has been a matter of
controversy whether measuring non–HDL-C or apolipo-
protein B concentrations are useful among primary preven-
tion individuals treated with statin therapy, and whether
either measure—or both—should be used as an alternative
or in addition to LDL-C. Among primary prevention
populations, 2 prior trials (AFCAPS/TexCAPS and
CARDS) evaluated this question. On-treatment apolipo-
protein B was better as a predictor of events compared with
LDL-C in asymptomatic individuals with low HDL-C in
AFCAPS/TexCAPS, although non–HDL-C was not eval-
uated in that study (12). Among diabetic patients in
CARDS, none of the on-treatment lipids or apolipopro-
teins were statistically significantly associated with risk in
the statin-allocated arm (although LDL-C and the LDL-
C/HDL-C ratio were borderline significant) (9,13). The
present JUPITER analysis, which was conducted among
primary prevention individuals who were nondiabetic and
without dyslipidemia, adds to the prior literature in finding
that measuring LDL-C alone was as valuable as measuring
non–HDL-C, apolipoprotein B, or the ratios (total
cholesterol/HDL-C, LDL-C/HDL-C, and apolipoprotein B/
A-I) in relation to residual risk.
Data from secondary prevention trials that evaluated the
predictive value of LDL-C, non–HDL-C, and apolipopro-
tein B in relation to recurrent events also have been mixed
and inconclusive (14,21,22). In the 4S (Scandinavian Sim-
vastatin Survival Study) study (21), on-treatment LDL-C
was comparable with non–HDL-C or the total cholesterol/
HDL-C ratio, whereas apolipoprotein B had weaker asso-
ciation with recurrent events. In the LIPID (Long-term
Intervention with Pravastatin in Ischemic Disease) Trial
(22), on-treatment apolipoprotein B had a stronger associ-
ation than LDL-C, although non–HDL-C was not re-
ported. In the combined analysis from the TNT (Treating
to New Targets) trial and IDEAL (Incremental Decrease in
End Points through Aggressive Lipid Lowering) trials,
which compared potent versus less intensive statin therapy
for the secondary prevention of cardiovascular disease (14),
on–HDL-C and apolipoprotein B were comparable in
elation to risk. Compared with TNT/IDEAL, the JUPI-
ER on-statin arm achieved lower levels of lipids and
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April 24, 2012:1521–8 Lipids, Apolipoproteins, and Residual RiskRisk of First CVD Event or Death for On-Treatment Lipids,Apolipoproteins, and Ratios According to Tertil sTable 2 Ri k of Firs CVD Event or Death for On-Treatment Lipids,Apolipoproteins, and Ratios According to Tertiles
Variable Tertile 1 Tertile 2 Tertile 3 p Value for linear trend
Lipids
TC (mg/dl) 123 123–145 145
No. CVD/no. CVD or death/total N 37/60/2,726 22/36/2,498 42/69/2,608
CVD incidence rate 0.60 0.40 0.78
CVD HRadjusted (95% CI) 1.00 0.75 (0.44–1.28) 1.53 (0.96–2.45) 0.04
CVD/death HRadjusted (95% CI) 1.00 0.72 (0.47–1.09) 1.47 (1.02–2.11) 0.02
LDL-C (mg/dl) 48 48–64 64
No. CVD/no. CVD or death/total N 30/53/2,628 23/40/2,618 48/72/2,586
CVD incidence rate 0.51 0.39 0.91
CVD HRadjusted (95% CI) 1.00 0.83 (0.48–1.43) 1.99 (1.25–3.19) 0.0007
CVD/death HRadjusted (95% CI) 1.00 0.78 (0.52–1.18) 1.63 (1.13–2.34) 0.002
Non–HDL-C (mg/dl) 69 69–88 88
No. CVD/no. CVD or death/total N 31/52/2,713 31/46/2,595 39/67/2,524
CVD incidence rate 0.52 0.53 0.75
CVD HRadjusted (95% CI) 1.00 1.11 (0.67–1.84) 1.64 (1.01–2.66) 0.03
CVD/death HRadjusted (95% CI) 1.00 0.98 (0.66–1.46) 1.72 (1.19–2.48) 0.001
Triglycerides (mg/dl) 83 83–121 121
No. CVD/no. CVD or death/total N 35/53/2,663 30/52/2,581 36/60/2,588
CVD incidence rate 0.61 0.54 0.62
CVD HRadjusted (95% CI) 1.00 0.94 (0.58–1.55) 1.06 (0.65–1.73) 0.76
CVD/death HRadjusted (95% CI) 1.00 1.12 (0.76–1.66) 1.31 (0.89–1.93) 0.16
HDL-C (mg/dl) 47 47–59 59
No. CVD/no. CVD or death/total N 41/67/2,770 27/48/2,522 33/50/2,540
CVD incidence rate 0.66 0.50 0.60
CVD HRadjusted (95% CI) 1.00 0.80 (0.48–1.33) 1.04 (0.63–1.71) 0.84
CVD/death HRadjusted (95% CI) 1.00 0.85 (0.56–1.24) 0.83 (0.56–1.23) 0.36
Apolipoproteins
Apolipoprotein A-I (mg/dl) 152 152–179 179
No. CVD/no. CVD or death/total N 36/64/2,612 40/62/2,649 25/39/2,571
CVD incidence rate 0.64 0.69 0.44
CVD HRadjusted (95% CI) 1.00 1.06 (0.66–1.68) 0.76 (0.44–1.30) 0.33
CVD/death HRadjusted (95% CI) 1.00 0.92 (0.64–1.31) 0.59 (0.39–0.90) 0.01
Apolipoprotein B (mg/dl) 60 60–75 75
No. CVD/no. CVD or death/total N 29/48/2,660 30/46/2,628 42/71/2,544
CVD incidence rate 0.50 0.50 0.78
CVD HRadjusted (95% CI) 1.00 1.01 (0.60–1.68) 1.60 (0.98–2.59) 0.04
CVD/death HRadjusted (95% CI) 1.00 0.91 (0.61–1.37) 1.64 (1.13–2.38) 0.003
Ratios
TC/HDL-C 2.23 2.23–2.83 2.83
No. CVD/no. CVD or death/total N 31/48/2,613 32/49/2,613 38/68/2,606
CVD incidence rate 0.54 0.55 0.68
CVD HRadjusted (95% CI) 1.00 1.04 (0.63–1.73) 1.27 (0.77–2.10) 0.31
CVD/death HRadjusted (95% CI) 1.00 1.10 (0.73–1.65) 1.63 (1.11–2.39) 0.008
LDL-C/HDL-C 0.87 0.87–1.29 1.29
No. CVD/no. CVD or death/total N 25/45/2,611 33/54/2,611 43/66/2,610
CVD incidence rate 0.43 0.56 0.79
CVD HRadjusted (95% CI) 1.00 1.20 (0.70–2.03) 1.82 (1.10–3.02) 0.01
CVD/death HRadjusted (95% CI) 1.00 1.15 (0.77–1.73) 1.64 (1.11–2.42) 0.008
Apolipoprotein B/A-I 0.35 0.35–0.47 0.47
No. CVD/no. CVD or death/total N 25/42/2,611 29/42/2,611 47/81/2,610
CVD incidence rate 0.43 0.49 0.86
CVD HRadjusted (95% CI) 1.00 1.15 (0.66–1.98) 1.96 (1.18–3.25) 0.004
CVD/death HRadjusted (95% CI) 1.00 1.02 (0.66–1.57) 2.12 (1.44–3.12) 0.0001
Incidence rates are per 100 person-years. HRs were adjusted for sex, age, smoking status, family history of premature atherosclerosis, body mass
index, systolic blood pressure, and fasting glucose.
CVD  cardiovascular disease; HR  hazard ratio; other abbreviations as in Table 1.
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CVD that were generally similar to TNT/IDEAL (Online
Table 1). Among acute coronary syndrome patients in the
PROVE IT–TIMI 22 trial, on-treatment apolipoprotein B
was equivalent to LDL-C or non–HDL-C (23).
An unresolved important question relates to the optimal
treatment targets of statin therapy for primary prevention.
Subgroup analyses from the current study suggest that the
magnitude of overall residual risk is small, and that most of the
associations with CVD were attenuated below levels of
LDL-C, non–HDL-C, or apolipoprotein B that corresponded
to established targets previously derived from secondary pre-
vention trials (LDL-C 70, non–HDL-C 100 mg/dl, or
polipoprotein B 80 mg/dl). The current data also do not
upport obtaining more than one of these measures in addition
o LDL-C for assessing residual risk. These results, however,
Risk of First CVD Event or Death for StandardizedOn-Treatment Lipids, Apolipoproteins, and RatioTable 3 Risk of First CVD Event or De th forOn-Treatment Lipids, Apolipoprotein
Variable SD
Standardize
(95%
Lipids
TC (mg/dl) 33.1
CVD 1.19 (0.
CVD/death 1.21 (1.
LDL-C (mg/dl) 27.4
CVD 1.31 (1.
CVD/death 1.29 (1.
Non–HDL-C (mg/dl) 30.8
CVD 1.25 (1.
CVD/death 1.28 (1.
Triglycerides (mg/dl) 62.7
CVD 0.93 (0.
CVD/death 1.04 (0.
HDL-C (mg/dl) 16.3
CVD 0.89 (0.
CVD/death 0.86 (0.
Apolipoproteins
Apolipoprotein A-I (mg/dl) 32.4
CVD 0.81 (0.
CVD/death 0.77 (0.
Apolipoprotein B (mg/dl) 22.1
CVD 1.27 (1.
CVD/death 1.30 (1.
Ratios
TC/HDL-C 0.86
CVD 1.22 (1.
CVD/death 1.24 (1.
LDL-C/HDL-C 0.65
CVD 1.29 (1.
CVD/death 1.29 (1.
Apolipoprotein B/A-I 0.17
CVD 1.27 (1.
CVD/death 1.30 (1.
Standardized HRs were adjusted for sex, age, smoking status, family h
and fasting glucose. *Likelihood ratio chi-square and p values obtained
the lipid variable to a referent model (nonlipid covariates only). A high
Abbreviations as in Tables 1 and 2.hould be considered exploratory because they were derived prom subgroup analysis and remain to be tested in a prospective
linical trial in the primary prevention setting.
riglycerides and residual risk. Another area of recent
ontroversy has been whether triglycerides contribute to
isk among statin-treated individuals compared with
ntreated individuals. The lack of association for on-
reatment triglycerides with residual risk in JUPITER is
upported by most previous statin trials, which also found
o significant associations for on-treatment triglycerides
12,21,24,25), as well as data from a meta-analysis (26).
mportantly, however, in the current JUPITER trial as
ell as in former statin trials, those with the highest
riglyceride levels were excluded, and most included
ndividuals had relatively low on-treatment triglyceride
evels. Therefore, we cannot exclude the possibility that
igher on-treatment triglycerides may be important for
ardized
d Ratios
djusted
p Value
Likelihood Ratio Chi-Square*
(p Value)
5) 0.08 2.84 (0.09)
1) 0.02 5.45 (0.02)
6) 0.004 7.64 (0.006)
9) 0.0004 11.44 (0.0007)
0) 0.02 5.18 (0.02)
7) 0.0005 10.69 (0.001)
7) 0.56 0.36 (0.55)
1) 0.57 0.30 (0.58)
2) 0.29 1.15 (0.28)
3) 0.10 2.90 (0.09)
1) 0.06 3.50 (0.06)
2) 0.003 9.15 (0.002)
3) 0.009 6.13 (0.01)
9) 0.0003 12.05 (0.0005)
4) 0.02 4.59 (0.03)
1) 0.0009 9.41 (0.002)
2) 0.002 7.85 (0.005)
6) 0.0001 13.11 (0.0003)
9) 0.003 7.37 (0.007)
6) 0.0001 15.85 (0.0001)
f premature atherosclerosis, body mass index, systolic blood pressure,
he Cox proportional hazards regression comparing models that added
quare value indicates a better model fit.sStand
s, an
d HRa
CI)
98–1.4
04–1.4
09–1.5
12–1.4
04–1.5
11–1.4
74–1.1
90–1.2
70–1.1
72–1.0
65–1.0
65–0.9
06–1.5
13–1.4
03–1.4
09–1.4
09–1.5
14–1.4
09–1.4
16–1.4
istory o
from tredicting residual risk.
sclerosi
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April 24, 2012:1521–8 Lipids, Apolipoproteins, and Residual RiskStudy limitations. The current study has potential limita-
tions. Median duration of follow-up in JUPITER was 1.9
years (maximum 5.0 years) due to early termination of the trial
for benefit, and data for events occurring long-term could not
be assessed. JUPITER excluded individuals with knownCVD,
diabetes, or high triglyceride levels or who did not meet entry
criteria for LDL-C and hsCRP, and it is unclear if our results
would be applicable to other individuals from primary or
Risk of First CVD Event or Death for StandardizedOn-Treatment Lipids, Ap lipoproteins, and Rat os According to SubTable 4 Risk of First CVD Ev nt or Death f r StandardizedOn-Treatment Lipids, Apolipoproteins, and Ratios Acco
Variable
LDL-C 100 mg/dl (no. CVD/no. CVD or death/total N: 86/140/6,970)
LDL-C
Non–HDL-C
Apolipoprotein B
TC/HD-C
LDL-C/HDL-C
Apolipoprotein B/A-I
LDL-C 70 mg/dl (no. CVD/no. CVD or death/total N: 61/103/5,793)
LDL-C
Non–HDL-C
Apolipoprotein B
TC/HDL-C
LDL-C/HDL-C
Apolipoprotein B/A-I
Non–HDL-C 130 mg/dl (no. CVD/no. CVD or death/total N: 87/141/7,035)
LDL-C
Non–HDL-C
Apolipoprotein B
TC/HDL-C
LDL-C/HDL-C
Apolipoprotein B/A-I
Non–HDL-C 100 mg/dl (no. CVD/no. CVD or death/total N: 70/114/6,108)
LDL-C
Non–HDL-C
Apolipoprotein B
TC/HDL-C
LDL/HDL-C
Apolipoprotein B/A-I
Apolipoprotein B 90 mg/dl (no. CVD/no. CVD or death/total N: 76/125/6,511)
LDL-C
Non–HDL-C
Apolipoprotein B
TC/HDL-C
LDL-C/HDL-C
Apolipoprotein B/A-I
Apolipoprotein B 80 mg/dl (no. CVD/no. CVD or death/total N: 66/107/5,798)
LDL-C
Non–HDL-C
Apolipoprotein B
Total/HDL-C
LDL-C/HDL-C
Apolipoprotein B/A–I
Standardized HRs were adjusted for sex, age, smoking status, family history of premature athero
Abbreviations as in Tables 1 and 2.secondary prevention who were excluded from the trial.JUPITER was a randomized clinical trial that tested a fixed
dose of a potent statin and did not test the efficacy of different
doses of statins nor did it test a strategy based on achieving
different lipid targets. Finally, although standardized regression
coefficients provide some ability to compare effect sizes across
biomarkers, they are dependent on the study-specific variability of
these biomarkers, which is influenced by the trial eligibility criteria.
Study strengths. Strengths of the current study are the
s
to Subgroups
CVD CVD/Death
andardized HRadjusted
(95% CI) p Value
Standardized HRadjusted
(95% CI) p Value
1.70 (1.22–2.36) 0.002 1.47 (1.13–1.91) 0.004
1.31 (0.97–1.79) 0.08 1.34 (1.05–1.71) 0.02
1.40 (1.05–1.86) 0.02 1.35 (1.08–1.70) 0.009
1.15 (0.90–1.48) 0.26 1.18 (0.97–1.42) 0.10
1.43 (1.09–1.88) 0.01 1.34 (1.07–1.67) 0.01
1.31 (1.07–1.61) 0.009 1.30 (1.12–1.51) 0.001
0.96 (0.56–1.73) 0.96 0.88 (0.58–1.36) 0.57
0.66 (0.39–1.12) 0.13 0.85 (0.57–1.28) 0.44
0.88 (0.56–1.37) 0.56 1.00 (0.71–1.40) 0.96
0.92 (0.61–1.37) 0.67 1.05 (0.79–1.40) 0.73
1.17 (0.72–1.89) 0.52 1.15 (0.80–1.66) 0.46
1.18 (0.86–1.62) 0.31 1.24 (1.01–1.53) 0.04
1.58 (1.18–2.13) 0.002 1.37 (1.08–1.74) 0.01
1.36 (0.99–1.88) 0.06 1.36 (1.06–1.76) 0.02
1.40 (1.04–1.87) 0.03 1.35 (1.07–1.70) 0.01
1.15 (0.87–1.53) 0.33 1.20 (0.97–1.49) 0.10
1.41 (1.07–1.86) 0.02 1.32 (1.05–1.65) 0.02
1.29 (1.05–1.60) 0.02 1.29 (1.11–1.51) 0.001
1.26 (0.79–2.01) 0.33 1.11 (0.77–1.59) 0.58
0.98 (0.59–1.62) 0.93 1.05 (0.71–1.57) 0.79
1.14 (0.74–1.73) 0.56 1.10 (0.79–1.53) 0.58
1.05 (0.71–1.56) 0.79 1.12 (0.83–1.50) 0.45
1.29 (0.85–1.97) 0.24 1.22 (0.88–1.70) 0.24
1.23 (0.93–1.63) 0.14 1.26 (1.03–1.52) 0.02
1.44 (0.98–2.11) 0.06 1.25 (0.92–1.69) 0.15
1.12 (0.74–1.69) 0.60 1.23 (0.89–1.68) 0.21
1.29 (0.86–1.91) 0.22 1.30 (0.96–1.78) 0.09
1.03 (0.73–1.47) 0.86 1.14 (0.88–1.48) 0.34
1.31 (0.90–1.89) 0.16 1.24 (0.93–1.66) 0.14
1.23 (0.94–1.60) 0.12 1.28 (1.06–1.53) 0.009
1.38 (0.86–2.23) 0.18 1.15 (0.80–1.67) 0.45
1.05 (0.62–1.76) 0.86 1.08 (0.72–1.62) 0.72
1.27 (0.77–2.09) 0.36 1.18 (0.80–1.75) 0.41
0.96 (0.62–1.47) 0.84 1.05 (0.76–1.44) 0.78
1.20 (0.76–1.92) 0.44 1.15 (0.80–1.65) 0.45
1.18 (0.85–1.63) 0.32 1.22 (0.98–1.51) 0.08
s, body mass index, systolic blood pressure, and fasting glucose.group
rding
Stlarge number of individuals with baseline and on-treatment
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tion on cardiovascular risk factors. Finally, few previous
studies have examined individuals from primary prevention
who had baseline low or average LDL-C levels and who
attained even lower LDL-C concentrations with potent
therapy.
Conclusions
In this large randomized, primary prevention trial of non-
diabetic individuals with elevated hsCRP and low LDL-C,
on-treatment LDL-C was as valuable as non–HDL-C,
apolipoprotein B, and several ratios in the prediction of
residual risk. Among participants achieving on-treatment
concentrations of LDL-C 70 mg/dl, non–HDL-C 100
g/dl, or apolipoprotein B 80 mg/dl, the overall magni-
ude of residual risk was small, and the risk associated with
hese measures decreased and was no longer statistically
ignificant. Finally, the current study does not support the
outine measurement of triglycerides among nondiabetic
ndividuals without significant dyslipidemia who are treated
ith potent statin therapy.
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